Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Here's Why AnaptysBio Rose 22.1% in May

TheMotleyFool

0 0

Shares of AnaptysBio (NASDAQ: ANAB) jumped over 22% last month, according to data provided by S&P Global Market Intelligence. The beaten-up biopharma stock trekked higher after the development-stage company delivered a slew of pipeline updates alongside first quarter 2020 operating results.

Investors aren't quite ready to forget the high-profile failure of etokimab in late 2019, but enthusiasm appears to be building for the company's pipeline. The small-cap stock has now gained 28% since the beginning of 2020, although shares of AnaptysBio have lost 73% in the last year.

Image source: Getty Images.

Source Fool.com

Like: 0

ANAB

Teilen